Healthcare utilization of patients accessing an African national treatment program

The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is l...

Full description

Saved in:
Bibliographic Details
Published inBMC health services research Vol. 7; no. 1; p. 80
Main Authors Harling, Guy, Orrell, Catherine, Wood, Robin
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 07.06.2007
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced. This paper describes healthcare utilization from program entry by treatment-naïve patients in a peri-urban settlement in South Africa. Treatment criteria included a CD4 cell count <200 cells/microl or an AIDS-defining illness. Data on health service utilization were collected retrospectively from the primary-care clinic and secondary and tertiary referral hospitals. Hospital visits were reviewed to determine the clinical reason for each visit. 212 patients were followed for a median of 490 days. Outpatient visits per 100 patient years of observation (PYO), excluding scheduled primary-care follow-up, fell from 596 immediately prior to ART to 334 in the first 48 weeks on therapy and 245 thereafter. Total inpatient time fell from 2,549 days per 100 PYO pre-ART to 476 in the first 48 weeks on therapy and 73 thereafter. This fall in healthcare utilization occurred at every level of care. The greatest causes of utilization were tuberculosis, cryptococcal meningitis, HIV-related neoplasms and adverse reactions to stavudine. After 48 weeks on ART demand reverted to primarily non-HIV-related causes. Utilization of both inpatient and outpatient hospital services fell significantly after commencement of ART for South African patients in the public sector, with inpatient demand falling fastest. Earlier initiation might reduce early on-ART utilization rates.
AbstractList BACKGROUND: The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced. METHODS: This paper describes healthcare utilization from program entry by treatment-naïve patients in a peri-urban settlement in South Africa. Treatment criteria included a CD4 cell count <200 cells/μl or an AIDS-defining illness. Data on health service utilization were collected retrospectively from the primary-care clinic and secondary and tertiary referral hospitals. Hospital visits were reviewed to determine the clinical reason for each visit. RESULTS: 212 patients were followed for a median of 490 days. Outpatient visits per 100 patient years of observation (PYO), excluding scheduled primary-care follow-up, fell from 596 immediately prior to ART to 334 in the first 48 weeks on therapy and 245 thereafter. Total inpatient time fell from 2,549 days per 100 PYO pre-ART to 476 in the first 48 weeks on therapy and 73 thereafter. This fall in healthcare utilization occurred at every level of care. The greatest causes of utilization were tuberculosis, cryptococcal meningitis, HIV-related neoplasms and adverse reactions to stavudine. After 48 weeks on ART demand reverted to primarily non-HIV-related causes. CONCLUSION: Utilization of both inpatient and outpatient hospital services fell significantly after commencement of ART for South African patients in the public sector, with inpatient demand falling fastest. Earlier initiation might reduce early on-ART utilization rates.
Abstract Background The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced. Methods This paper describes healthcare utilization from program entry by treatment-naïve patients in a peri-urban settlement in South Africa. Treatment criteria included a CD4 cell count <200 cells/μl or an AIDS-defining illness. Data on health service utilization were collected retrospectively from the primary-care clinic and secondary and tertiary referral hospitals. Hospital visits were reviewed to determine the clinical reason for each visit. Results 212 patients were followed for a median of 490 days. Outpatient visits per 100 patient years of observation (PYO), excluding scheduled primary-care follow-up, fell from 596 immediately prior to ART to 334 in the first 48 weeks on therapy and 245 thereafter. Total inpatient time fell from 2,549 days per 100 PYO pre-ART to 476 in the first 48 weeks on therapy and 73 thereafter. This fall in healthcare utilization occurred at every level of care. The greatest causes of utilization were tuberculosis, cryptococcal meningitis, HIV-related neoplasms and adverse reactions to stavudine. After 48 weeks on ART demand reverted to primarily non-HIV-related causes. Conclusion Utilization of both inpatient and outpatient hospital services fell significantly after commencement of ART for South African patients in the public sector, with inpatient demand falling fastest. Earlier initiation might reduce early on-ART utilization rates.
The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced. This paper describes healthcare utilization from program entry by treatment-naïve patients in a peri-urban settlement in South Africa. Treatment criteria included a CD4 cell count <200 cells/microl or an AIDS-defining illness. Data on health service utilization were collected retrospectively from the primary-care clinic and secondary and tertiary referral hospitals. Hospital visits were reviewed to determine the clinical reason for each visit. 212 patients were followed for a median of 490 days. Outpatient visits per 100 patient years of observation (PYO), excluding scheduled primary-care follow-up, fell from 596 immediately prior to ART to 334 in the first 48 weeks on therapy and 245 thereafter. Total inpatient time fell from 2,549 days per 100 PYO pre-ART to 476 in the first 48 weeks on therapy and 73 thereafter. This fall in healthcare utilization occurred at every level of care. The greatest causes of utilization were tuberculosis, cryptococcal meningitis, HIV-related neoplasms and adverse reactions to stavudine. After 48 weeks on ART demand reverted to primarily non-HIV-related causes. Utilization of both inpatient and outpatient hospital services fell significantly after commencement of ART for South African patients in the public sector, with inpatient demand falling fastest. Earlier initiation might reduce early on-ART utilization rates.
Abstract Background The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced. Methods This paper describes healthcare utilization from program entry by treatment-naïve patients in a peri-urban settlement in South Africa. Treatment criteria included a CD4 cell count <200 cells/μl or an AIDS-defining illness. Data on health service utilization were collected retrospectively from the primary-care clinic and secondary and tertiary referral hospitals. Hospital visits were reviewed to determine the clinical reason for each visit. Results 212 patients were followed for a median of 490 days. Outpatient visits per 100 patient years of observation (PYO), excluding scheduled primary-care follow-up, fell from 596 immediately prior to ART to 334 in the first 48 weeks on therapy and 245 thereafter. Total inpatient time fell from 2,549 days per 100 PYO pre-ART to 476 in the first 48 weeks on therapy and 73 thereafter. This fall in healthcare utilization occurred at every level of care. The greatest causes of utilization were tuberculosis, cryptococcal meningitis, HIV-related neoplasms and adverse reactions to stavudine. After 48 weeks on ART demand reverted to primarily non-HIV-related causes. Conclusion Utilization of both inpatient and outpatient hospital services fell significantly after commencement of ART for South African patients in the public sector, with inpatient demand falling fastest. Earlier initiation might reduce early on-ART utilization rates.
BACKGROUNDThe roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced.METHODSThis paper describes healthcare utilization from program entry by treatment-naïve patients in a peri-urban settlement in South Africa. Treatment criteria included a CD4 cell count <200 cells/microl or an AIDS-defining illness. Data on health service utilization were collected retrospectively from the primary-care clinic and secondary and tertiary referral hospitals. Hospital visits were reviewed to determine the clinical reason for each visit.RESULTS212 patients were followed for a median of 490 days. Outpatient visits per 100 patient years of observation (PYO), excluding scheduled primary-care follow-up, fell from 596 immediately prior to ART to 334 in the first 48 weeks on therapy and 245 thereafter. Total inpatient time fell from 2,549 days per 100 PYO pre-ART to 476 in the first 48 weeks on therapy and 73 thereafter. This fall in healthcare utilization occurred at every level of care. The greatest causes of utilization were tuberculosis, cryptococcal meningitis, HIV-related neoplasms and adverse reactions to stavudine. After 48 weeks on ART demand reverted to primarily non-HIV-related causes.CONCLUSIONUtilization of both inpatient and outpatient hospital services fell significantly after commencement of ART for South African patients in the public sector, with inpatient demand falling fastest. Earlier initiation might reduce early on-ART utilization rates.
Background The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced. Methods This paper describes healthcare utilization from program entry by treatment-naive patients in a peri-urban settlement in South Africa. Treatment criteria included a CD4 cell count &200 cells/ mu l or an AIDS-defining illness. Data on health service utilization were collected retrospectively from the primary-care clinic and secondary and tertiary referral hospitals. Hospital visits were reviewed to determine the clinical reason for each visit. Results 212 patients were followed for a median of 490 days. Outpatient visits per 100 patient years of observation (PYO), excluding scheduled primary-care follow-up, fell from 596 immediately prior to ART to 334 in the first 48 weeks on therapy and 245 thereafter. Total inpatient time fell from 2,549 days per 100 PYO pre-ART to 476 in the first 48 weeks on therapy and 73 thereafter. This fall in healthcare utilization occurred at every level of care. The greatest causes of utilization were tuberculosis, cryptococcal meningitis, HIV-related neoplasms and adverse reactions to stavudine. After 48 weeks on ART demand reverted to primarily non-HIV-related causes. Conclusion Utilization of both inpatient and outpatient hospital services fell significantly after commencement of ART for South African patients in the public sector, with inpatient demand falling fastest. Earlier initiation might reduce early on-ART utilization rates.
ArticleNumber 80
Audience Academic
Author Harling, Guy
Orrell, Catherine
Wood, Robin
AuthorAffiliation 1 The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
AuthorAffiliation_xml – name: 1 The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
Author_xml – sequence: 1
  givenname: Guy
  surname: Harling
  fullname: Harling, Guy
  email: Guy.Harling@gmail.com
  organization: The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa. Guy.Harling@gmail.com
– sequence: 2
  givenname: Catherine
  surname: Orrell
  fullname: Orrell, Catherine
– sequence: 3
  givenname: Robin
  surname: Wood
  fullname: Wood, Robin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17555564$$D View this record in MEDLINE/PubMed
BookMark eNqFkt9rFDEQx4NU7A999VEWBN-2JtlsfrwIR1FbKAiizyGZTa4pu8mZ7BX0rzfbO2oPKyYPM8x880kmM6foKKboEHpN8Dkhkr8nTNCWK961opX4GTp5CBw98o_RaSm3GBMhqXiBjono6-LsBH29dGacb8Bk12znMIZfZg4pNsk3m-q5OJfGALhSQlw3JjYrnwNUG-91Zmzm7Mw8VWGzyWmdzfQSPfdmLO7V3p6h758-fru4bK-_fL66WF23lhM8t8bC4JWygA0Wig8CC6AcLLOktwDeWuoxsWAo0KFjCpQfFOcdFYApWNedoasdd0jmVm9ymEz-qZMJ-j6Q8lqbPAcYnVYMiKWsU0RKJp0z2Hkv5ECGXmBqaWV92LE2Wzu5AWo52YwH0MNMDDd6ne40kUoRwSpgtQPYkP4BOMxAmvTSH730RwstcWW82z8ipx9bV2Y9hQJuHE10aVu0wLyXjPD_CinueknUQny7E65N_YUQfap3wyLWK8J7rjrKSFWdP6Gqe3BTgDpvPtT4Uwcgp1Ky8w91EqyXsfy7sjePv_ePfD-H3W9PguDU
CitedBy_id crossref_primary_10_1186_1471_2458_10_387
crossref_primary_10_2202_1948_4682_1183
crossref_primary_10_1177_1545109712459077
crossref_primary_10_1007_s10461_011_0097_6
crossref_primary_10_1371_journal_pone_0069288
crossref_primary_10_1016_j_socscimed_2008_11_009
crossref_primary_10_1016_j_transci_2014_10_012
crossref_primary_10_1007_s12281_011_0070_x
crossref_primary_10_1007_s10461_023_04065_5
crossref_primary_10_1097_QCO_0b013e32832fa214
crossref_primary_10_1371_journal_pmed_1000189
crossref_primary_10_1371_journal_pone_0225742
crossref_primary_10_1089_apc_2007_0193
crossref_primary_10_1186_1472_6963_11_345
crossref_primary_10_1097_QCO_0b013e3283177f6c
crossref_primary_10_1186_1471_2334_9_205
Cites_doi 10.1111/j.1365-3156.2005.01390.x
10.1097/00126334-200205010-00003
10.1016/S0140-6736(02)08904-3
10.1371/journal.pmed.0030004
10.1177/135965350701200106
10.1016/S0140-6736(02)11478-4
10.1097/00002030-200403050-00006
10.1136/bmj.328.7434.241
10.2165/00019053-199915001-00002
10.1097/00002030-199902250-00015
10.1016/S0140-6736(02)09411-4
10.1016/S0140-6736(04)16597-5
10.1097/00002030-200007280-00019
10.1097/01.aids.0000191232.16111.f9
10.1097/01.aids.0000176211.08581.5a
10.1097/00042560-199807010-00006
10.1258/0956462011923336
10.1089/apc.2005.19.473
10.1097/01.qai.0000174251.35398.72
10.1097/01.qai.0000225729.79610.b7
ContentType Journal Article
Copyright COPYRIGHT 2007 BioMed Central Ltd.
Copyright © 2007 Harling et al; licensee BioMed Central Ltd. 2007 Harling et al; licensee BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2007 BioMed Central Ltd.
– notice: Copyright © 2007 Harling et al; licensee BioMed Central Ltd. 2007 Harling et al; licensee BioMed Central Ltd.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7U9
C1K
H94
M7N
7X8
5PM
DOA
DOI 10.1186/1472-6963-7-80
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Virology and AIDS Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
Virology and AIDS Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList

MEDLINE
CrossRef
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 1472-6963
EndPage 80
ExternalDocumentID oai_doaj_org_article_94c1b243918848eea0eff78d1d5702b2
oai_biomedcentral_com_1472_6963_7_80
A165693241
10_1186_1472_6963_7_80
17555564
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations South Africa
GeographicLocations_xml – name: South Africa
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: U19 AI053217
– fundername: NIAID NIH HHS
  grantid: R01AI058736-01A1
– fundername: NIAID NIH HHS
  grantid: R01 AI058736
– fundername: NIAID NIH HHS
  grantid: 1U19AI53217-01
GroupedDBID ---
-A0
0R~
23N
2VQ
2WC
4.4
44B
53G
5VS
6J9
6PF
7WY
8FL
AAFWJ
AAJSJ
AAWTL
ABDBF
ACGFO
ACGFS
ACIHN
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BFQNJ
BMC
C1A
C24
C6C
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
ECM
EIF
EJD
EMB
EMK
EMOBN
ESX
F5P
GROUPED_DOAJ
GX1
H13
HYE
IAO
IHR
INH
INR
IPNFZ
ITC
K60
K6~
KQ8
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
PQQKQ
RBZ
RIG
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
W2D
WOQ
WOW
XSB
AAYXX
CITATION
ABVAZ
AFGXO
AFNRJ
7QL
7U9
C1K
H94
M7N
7X8
5PM
ID FETCH-LOGICAL-b610t-abcdf99bc0a0796d707c26cb4b15bccfbb2f01bca2c2d349c9fd966327c02cbe3
IEDL.DBID RPM
ISSN 1472-6963
IngestDate Tue Oct 22 15:13:09 EDT 2024
Tue Sep 17 21:11:19 EDT 2024
Wed May 22 07:11:46 EDT 2024
Fri Aug 16 22:00:47 EDT 2024
Fri Aug 16 22:12:06 EDT 2024
Wed Mar 06 18:18:50 EST 2024
Tue Mar 05 06:12:03 EST 2024
Thu Sep 12 16:41:37 EDT 2024
Sat Sep 28 07:48:03 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b610t-abcdf99bc0a0796d707c26cb4b15bccfbb2f01bca2c2d349c9fd966327c02cbe3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1899174/
PMID 17555564
PQID 20358190
PQPubID 23462
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_94c1b243918848eea0eff78d1d5702b2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_1899174
biomedcentral_primary_oai_biomedcentral_com_1472_6963_7_80
proquest_miscellaneous_70658416
proquest_miscellaneous_20358190
gale_infotracmisc_A165693241
gale_infotracacademiconefile_A165693241
crossref_primary_10_1186_1472_6963_7_80
pubmed_primary_17555564
PublicationCentury 2000
PublicationDate 2007-06-07
PublicationDateYYYYMMDD 2007-06-07
PublicationDate_xml – month: 06
  year: 2007
  text: 2007-06-07
  day: 07
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC health services research
PublicationTitleAlternate BMC Health Serv Res
PublicationYear 2007
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 16116308 - Med Care. 2005 Sep;43(9 Suppl):III40-52
16260920 - AIDS. 2005 Nov 18;19(17):2050-2
16318413 - PLoS Med. 2006 Jan;3(1):e4
12433534 - Lancet. 2002 Nov 9;360(9344):1503-5
11368820 - Int J STD AIDS. 2001 Jun;12(6):386-9
12874156 - CMAJ. 2003 Jul 22;169(2):106-10
14751875 - BMJ. 2004 Jan 31;328(7434):241-2
16810113 - J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):464-9
12086758 - Lancet. 2002 Jun 15;359(9323):2059-64
16124841 - AIDS Patient Care STDS. 2005 Aug;19(8):473-85
15234864 - Lancet. 2004 Jul 3-9;364(9428):103-7
10199233 - AIDS. 1999 Feb 25;13(3):415-8
16670804 - S Afr Med J. 2006 Apr;96(4):315-20
15807791 - Trop Med Int Health. 2005 Apr;10(4):295-9
16123682 - J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):53-6
10537439 - Pharmacoeconomics. 1999;15 Suppl 1:13-22
15990564 - AIDS. 2005 Jul 22;19(11):1113-24
12048359 - J Acquir Immune Defic Syndr. 2002 May 1;30(1):21-6
12126821 - Lancet. 2002 Jul 13;360(9327):119-29
17503751 - Antivir Ther. 2007;12(1):83-8
15090767 - AIDS. 2004 Mar 5;18(4):621-30
9665500 - J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jul 1;18(3):234-40
10983650 - AIDS. 2000 Jul 28;14(11):1625-31
M Badri (421_CR25) 2002; 359
CB Holmes (421_CR24) 2006; 42
HIV Research Network (421_CR12) 2002; 30
G Arthur (421_CR8) 2000; 14
M Egger (421_CR18) 2002; 360
A Reid (421_CR9) 2005; 40
C Orrell (421_CR23) 2007; 12
LG Bekker (421_CR19) 2006; 96
421_CR20
HB Krentz (421_CR14) 2003; 169
R Loewenson (421_CR4) 2004; 328
C Gilks (421_CR7) 1998; 18
M Rabkin (421_CR5) 2002; 360
L Lacey (421_CR22) 1999; 15
421_CR2
SD Lawn (421_CR26) 2005; 19
M Badri (421_CR16) 2006; 3
K Kober (421_CR3) 2004; 364
JA Fleishman (421_CR13) 2005; 43
CR Uphold (421_CR21) 2005; 19
H Palacio (421_CR11) 2004; 18
M Colvin (421_CR10) 2001; 12
SD Lawn (421_CR17) 2005; 19
World Health Organisation (421_CR1) 2005
S Jaffar (421_CR6) 2005; 10
S Paul (421_CR15) 1999; 13
References_xml – volume: 10
  start-page: 295
  issue: 4
  year: 2005
  ident: 421_CR6
  publication-title: Trop Med Int Health
  doi: 10.1111/j.1365-3156.2005.01390.x
  contributor:
    fullname: S Jaffar
– volume: 30
  start-page: 21
  year: 2002
  ident: 421_CR12
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/00126334-200205010-00003
  contributor:
    fullname: HIV Research Network
– ident: 421_CR20
– volume: 359
  start-page: 2059
  year: 2002
  ident: 421_CR25
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)08904-3
  contributor:
    fullname: M Badri
– volume: 169
  start-page: 106
  issue: 2
  year: 2003
  ident: 421_CR14
  publication-title: CMAJ
  contributor:
    fullname: HB Krentz
– volume: 3
  start-page: e4
  issue: 1
  year: 2006
  ident: 421_CR16
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0030004
  contributor:
    fullname: M Badri
– volume: 12
  start-page: 83
  year: 2007
  ident: 421_CR23
  publication-title: Antiviral Therapy
  doi: 10.1177/135965350701200106
  contributor:
    fullname: C Orrell
– volume: 360
  start-page: 1503
  year: 2002
  ident: 421_CR5
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)11478-4
  contributor:
    fullname: M Rabkin
– volume: 18
  start-page: 621
  year: 2004
  ident: 421_CR11
  publication-title: AIDS
  doi: 10.1097/00002030-200403050-00006
  contributor:
    fullname: H Palacio
– ident: 421_CR2
– volume: 328
  start-page: 241
  year: 2004
  ident: 421_CR4
  publication-title: Br Med J
  doi: 10.1136/bmj.328.7434.241
  contributor:
    fullname: R Loewenson
– volume: 15
  start-page: 13
  issue: Suppl 1
  year: 1999
  ident: 421_CR22
  publication-title: Pharmacoeconomics
  doi: 10.2165/00019053-199915001-00002
  contributor:
    fullname: L Lacey
– volume: 13
  start-page: 415
  issue: 3
  year: 1999
  ident: 421_CR15
  publication-title: AIDS
  doi: 10.1097/00002030-199902250-00015
  contributor:
    fullname: S Paul
– volume-title: Progress on global access to HIV antiretroviral therapy: an update on "3 by 5"
  year: 2005
  ident: 421_CR1
  contributor:
    fullname: World Health Organisation
– volume: 360
  start-page: 119
  year: 2002
  ident: 421_CR18
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)09411-4
  contributor:
    fullname: M Egger
– volume: 364
  start-page: 103
  year: 2004
  ident: 421_CR3
  publication-title: Lancet
  doi: 10.1016/S0140-6736(04)16597-5
  contributor:
    fullname: K Kober
– volume: 14
  start-page: 1625
  issue: 11
  year: 2000
  ident: 421_CR8
  publication-title: AIDS
  doi: 10.1097/00002030-200007280-00019
  contributor:
    fullname: G Arthur
– volume: 19
  start-page: 2050
  issue: 17
  year: 2005
  ident: 421_CR17
  publication-title: AIDS
  doi: 10.1097/01.aids.0000191232.16111.f9
  contributor:
    fullname: SD Lawn
– volume: 96
  start-page: 315
  issue: 4
  year: 2006
  ident: 421_CR19
  publication-title: S Afr Med J
  contributor:
    fullname: LG Bekker
– volume: 43
  start-page: III-40
  issue: 9 Suppl
  year: 2005
  ident: 421_CR13
  publication-title: Med Care
  contributor:
    fullname: JA Fleishman
– volume: 19
  start-page: 1113
  year: 2005
  ident: 421_CR26
  publication-title: AIDS
  doi: 10.1097/01.aids.0000176211.08581.5a
  contributor:
    fullname: SD Lawn
– volume: 18
  start-page: 234
  issue: 3
  year: 1998
  ident: 421_CR7
  publication-title: J Acquir Immune Defic Syndr Hum Retrovirol
  doi: 10.1097/00042560-199807010-00006
  contributor:
    fullname: C Gilks
– volume: 12
  start-page: 386
  issue: 6
  year: 2001
  ident: 421_CR10
  publication-title: Int J STD AIDS
  doi: 10.1258/0956462011923336
  contributor:
    fullname: M Colvin
– volume: 19
  start-page: 473
  issue: 8
  year: 2005
  ident: 421_CR21
  publication-title: AIDS Patient Care STDs
  doi: 10.1089/apc.2005.19.473
  contributor:
    fullname: CR Uphold
– volume: 40
  start-page: 53
  year: 2005
  ident: 421_CR9
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/01.qai.0000174251.35398.72
  contributor:
    fullname: A Reid
– volume: 42
  start-page: 464
  year: 2006
  ident: 421_CR24
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/01.qai.0000225729.79610.b7
  contributor:
    fullname: CB Holmes
SSID ssj0017827
Score 1.9760478
Snippet The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services....
Abstract Background The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for...
Background The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare...
BACKGROUNDThe roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare...
BACKGROUND: The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare...
Abstract Background The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for...
SourceID doaj
pubmedcentral
biomedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 80
SubjectTerms Acquired Immunodeficiency Syndrome - drug therapy
Adult
Anti-Retroviral Agents - classification
Anti-Retroviral Agents - therapeutic use
Antiretroviral Therapy, Highly Active - utilization
Antiviral agents
CD4 Lymphocyte Count
Community Health Centers - utilization
Cryptococcus
Dosage and administration
Drug therapy
Evaluation
Female
Health Knowledge, Attitudes, Practice
Health Services Needs and Demand - trends
HIV infection
HIV Infections - drug therapy
HIV Infections - epidemiology
HIV Infections - pathology
Human immunodeficiency virus
Humans
Male
Management
Medical care
Medical policy
Mycobacterium
National Health Programs - utilization
Outpatient Clinics, Hospital - utilization
Retrospective Studies
South Africa - epidemiology
Urban Health Services - utilization
Utilization
SummonAdditionalLinks – databaseName: BiomedCentral
  dbid: RBZ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Na90wDDdbdxmM0XYfzdYPHwY7mdmOE9u7taXlUegOY4Wyi7Edmw1K3lhf__9K-Xit-9hpOcZyEkeSJdnSz4R8yo1vos41Myo3TCUbmc_Ss9oKowPCn3QYKF5-axdX6uK6uX5Y73iygy9M-0UoLVkLcsJwOn1OXkiEOMe4_OTner8A7NxwjMpMO8EzbvZ_Utd-U5ijAbV_c25-ZJzKxMlHluh8m7yeXEh6PPJ8hzxL_S55Na6_0bGs6A35vlgndlGQrZup3JIuM52gVG-pHw5LBNtFfU_HA4N6Oq8O0nUKOp1yuN6Sq_OzH6cLNp2fwAI4RSvmQ-yytSFyz7VtO811lG0MKogmxJhDkJmLEL2MsquVjTZ3EP3UUkcuY0j1O7LVL_u0R6gwvu7A9VEiadXkYLVNGFVHpVL2PlXka_Fb3Z8RK8MhenXZAorkkCcOeeK0M7win2cerPsNsYlpNyhPkEXF04cbIDBuUjVnVRRBYkWxMcqk5HnKWZtOdI3mMkh4HTLYoQbDF0U_FSLASBELyx0jIBG4tUpUZL-gBM2LRfPRLCIOmzBdrU_Lu1snOcLKWf5vCj24fqKtyPtRpB5Grhu4WlURXQhbMeiypf_9awAGFxA8Q4T54X-Y8ZG8nFMiud4nW6u_d-kA_K5VOBxU7h75SCxQ
  priority: 500
  providerName: BioMedCentral
– databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbxUhECemJxPTqK26Wi2HJp5IgYUFvFVj82KiB2OT3giwkDZp9hn7-v87LOzz0cZ4cY_AfgwzMDPszG8QOknSyaBST7RIkohoAnGJO9IbppXP8CdjdhS_fhtWF-LLpbzcKfWVY8IKPHCZuFMjAvM854dqLXSMjsaUlB7ZKBXlvuy-TC7OVP1_AHpvLqsiFCcDyFiFa2R6ON22kbw938tzv2nU04zi_3Cv3lFWbSDljmY6f4r2q0mJzwopz9CjOD1HT8p5HC5pRgfo-2ob6IVB1m5q-iVeJ1yhVW-xm4sngi7DbsKlgNCEl9NCvA1JxzWm6xBdnH_-8WlFaj0F4sFI2hDnw5iM8YE6qswwKqoCH4IXnkkfQvKeJ8p8cDzwsRcmmDSCN9RzFSgPPvYv0N60nuIrhJl2_QimkGBRCZm8USZmLzsIEZNzsUMfmmm1Pwt2hs1o1m0PLCybeWIzT6yymnbo_cKD7X2zr6KHByM_ZhY1T58bQIJslSD7LwmC12UG27yi4YuCq4kJQGnGxrJnGaAIzFzBOnTUjISVGJru40VEbO7K4WtTXN_dWk4zzJyhfx-hZlOQDR16WUTqD-VKwjWIDqlG2Bqi257p-moGCmfgTIPH-fp_zNIb9HgJlaTqCO1tft3Ft2CPbfy7een9BjigNBs
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwELagXJBQxZuUAj4gcTLYjhPbSAgVRLVCKgfESr1ZtmNTpFW23d1K7b_Hk3h3a5bmGD8SZ77JzCQznxF6GxvbeBlrokRsiAjaExu5JbVmSjqgP-kgUDz50U6m4vtpc7rNf8oPcPnf0A72k5ouZu-vLq4_J4X_NCi8aj8wITlpE5IIvHDvontc1ALQfiK2fxSSJZSZtHF3DFCHyiYd7b-F77PCXg20_rsv7xvWq8ysvGGqjh-i_exj4qMRFI_QndA_Rg_GD3R4rDt6gn5ONplfOIFvlusx8TzizLW6xHbYTTEZN2x7PO4o1OP150O8yVHHOcnrKZoef_v1dULyBgvEJa9pRazzXdTaeWqp1G0nqfS89U441jjvo3M8Uua85Z53tdBexy6FRzWXnnLvQv0M7fXzPrxAmClbd8k3EixI0USnpQ4QdnshQrQ2VOhj8VjN-UimYYDeumxJmmZAPAbEY6RRtELv1jLYjBuCF9Xu9PwCIipmH07MF79N1kWjhWeOQ8mxUkKFYGmIUaqOdY2k3PF0ORCwAdClO_I2VyqklQJZljkCxqLk9wpWocOiZ1JNXzS_WUPEQBPks_Vhfrk0nALvnKa395CDb8jaCj0fIbVdeUZqhWQBtmLRZUv_52xgDmcpuk4h6MGtc75E99cJkVQeor3V4jK8Sl7Xyr0e1OkvIbYsBg
  priority: 102
  providerName: Scholars Portal
Title Healthcare utilization of patients accessing an African national treatment program
URI https://www.ncbi.nlm.nih.gov/pubmed/17555564
https://search.proquest.com/docview/20358190
https://search.proquest.com/docview/70658416
http://dx.doi.org/10.1186/1472-6963-7-80
https://pubmed.ncbi.nlm.nih.gov/PMC1899174
https://doaj.org/article/94c1b243918848eea0eff78d1d5702b2
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELaAU6Wq6rsBSn2o1FNY23FimxugolWlrSpUJNSLZTt2i7RkESz_v2PH2eKiXppDDrHzcGYmM-N88xmhj6E1rROhqSUPbc29crUJzNSNolLYSH_Sx0Rx8bWbX_Avl-3lFmqnWpgE2nf26nBYXh8OV78StvLm2s0mnNjs2-KUQpIAkfRsG22LpplS9PzrAFyeyOyMVHYzygWrO1CzOn6NI0eoaGHr_q5wXxaOKfH3P_5KP3BTJYTygU86e46e5WASH48P_QJt-eElejrOxOGxwOgVOp9vIF4YtGyZCy_xKuBMqnqHTVo2EbwYNgMelw4a8DRPiDdgdJzRXK_Rxdnn76fzOq-kUFsIj9a1sa4PSllHDBGq6wURjnXOcktb61ywlgVCrTPMsb7hyqnQQx7UMOEIc9Y3b9DOsBr8O4SpNE0PQRCnXvA2WCWUj_m149wHY3yFjorXqm9G1gwdeazLFjApHcWjo3i00JJU6NMkg815KUuR3aOeJ1FExdXTgdXtT511RSvuqGWxtlhKLr03xIcgZE_7VhBmGdwuClhHW4YnciaXJMBIIyuWPo7URBDgclqh_aIn2KArmj9MKqJjUwSuDX51f6cZiQRzivy7h0hBIO0q9HZUqT8jz5paIVEoWzHosgUsJlGEZwvZ_e8z99CTCRlJxD7aWd_e-_cQfq3tQZq2gP2CS9ifn_w4SAb4G4RiNd4
link.rule.ids 108,230,315,733,786,790,870,891,2115,2236,24346,24965,27955,27956,53825,53827,76167,76168
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED6N8QAS4vegMJgfkHhKazt2HPM2JqYC64TQhvZm2Y4NE106be0Lfz124pR5Ew_Qx5yT9nR3vrv0u88AbzzX3ApfFjXzvGBO2kJ7qotSklqYSH_SxEZxdlhNj9mnE36yAXyYhelA-9acjtv52bg9_dFhK8_P7GTAiU2-zPZIaBJCJT25BbdDvFI-NOnpz4OQ9ETiZyR1NSFM0KIKjlbE_TiyhAoePtX1Gfd5lpo6Bv-b-_SVRJWDKK9kpf0H8G3Qpwej_ByvlmZsf12jevxnhR_C_VSnot1e_Ag2XPsY7vUv-VA_u_QEvk7X6DEUHHieZjrRwqPE13qJdHciY0iQSLeoP5WoRcMrSLTGuaMEFHsKx_sfjvamRTqkoTCh8loW2tjGS2ks1ljIqhFYWFpZwwzhxlpvDPWYGKuppU3JpJW-CS1WSYXF1BpXbsFmu2jdc0Ck1mUT6itGnGDcGymki627Zcx5rd0I3mX2Uuc9IYeKFNm5JESrinZX0e5KqBqP4O1g3PV9XQNUVzdWvo-2z57eXVhcfFfJKkoySwyNY8t1zWrnNHbei7ohDReYGhq-LnqOittE-EVWp2mHoGkk3FK7kfUo1M6MjGA7WxnC22bincH3VBRFTFzrFqtLRXHkrpP47ytEV1-SagTPel_9o3kKgRGIzIszpXNJ8M2OfTz54ov_vnMH7kyPZgfq4OPh55dwdwBgYrENm8uLlXsVqryled3F9G_icFT9
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSAip4v0IFOoDEqfs2o4T29xKYbU8WlWIShUXy57YUHWbXbW7F349duIsm1ZcmmPsPEYz45lJvvmM0FtfmhKEL3LJfZlzpyA3npm8UFQKG-lP6lgoHhxW02P-5aQ82djqqwXtgz0dNbPzUXP6u8VWLs5h3OPExkcH-zQUCSGTHi9qP76N7gSfZaIv1NMPhBD4ROJopLIaUy5YXgVjy-OaHJlCRRmO6mqf-2wQnloW_-tr9UawGgIpNyLT5AH62cvUAVLORqulHcGfK3SPNxL6Ibqf8lW81015hG655jHa7j724a6H6Qn6Pl2jyHAw5Fnq7cRzjxNv6yU27c6MIVBi0-Bud6IG958i8RrvjhNg7Ck6nnz6sT_N02YNuQ0Z2DI3FmqvlAViiFBVLYgAVoHllpYWwFvLPKEWDANWF1yB8nUotQomgDCwrniGtpp5414gTKUp6pBnceoEL71VQrlYwgPnzhvjMvR-oDO96Ig5dKTKHo4Er9VR9zrqXgstSYbe9QpeX9cWQrK6NvND1P_g7u2J-cUvnTSjFQdqWWxflpJL5wxx3gtZ07oUhFkWHhetR8flIrwRmNT1ECSNxFt6L7IfhRya0wztDGYGN4fB8G5vfzoORWxc4-arS81I5LBT5P8zRJtn0ipDzzt7_Sd5coMMiYElD4QejgT7bFnIkz2-vPGVu-ju0ceJ_vb58OsrdK_HYRKxg7aWFyv3OiR7S_umdeu_V4hXfQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Healthcare+utilization+of+patients+accessing+an+African+national+treatment+program&rft.jtitle=BMC+health+services+research&rft.au=Harling%2C+Guy&rft.au=Orrell%2C+Catherine&rft.au=Wood%2C+Robin&rft.date=2007-06-07&rft.eissn=1472-6963&rft.volume=7&rft.spage=80&rft_id=info:doi/10.1186%2F1472-6963-7-80&rft_id=info%3Apmid%2F17555564&rft.externalDocID=17555564
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6963&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6963&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6963&client=summon